Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Aleksandr Obikhod"'
Autor:
Leda Bassit, Aleksandr Obikhod, Marcia M. Clayton, Alla Arzumanyan, Raymond F. Schinazi, James J. Kohler, Mark A. Feitelson, Bill N. C. Sun
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:6186-6191
Next-generation therapies for chronic hepatitis B virus (HBV) infection will involve combinations of established and/or experimental drugs. The current study investigated the in vitro and in vivo efficacy of tenofovir disoproxil fumarate (TDF) and/or
Autor:
Andy I. M. Hoepelman, Dorien de Jong, Noortje M van Maarseveen, Greg L. Beilhartz, Raymond F. Schinazi, Annemarie M. J. Wensing, Joop E. Arends, Aleksandr Obikhod, Matthias Götte, Monique Nijhuis, Sijia Tao, Marieke Pingen
Publikováno v:
Antivir Ther
Background HIV–HBV-coinfected individuals who need to be treated only for their HBV infection have limited therapeutic options, since most approved anti-HBV agents have a risk of selecting for drug-resistant HIV mutants. In vivo data are inconclusi
Autor:
Ugo Pradere, Aleksandr Obikhod, Hongwang Zhang, John W. Mellors, Raymond F. Schinazi, Richard A. Stanton, Nicolas Sluis-Cremer, James H. Nettles, Steven J. Coats, Mervi Detorio, Brian D. Herman
Publikováno v:
Nucleic Acids Research
β-D-3'-Azido-2',3'-dideoxyguanosine (3'-azido-ddG) is a potent inhibitor of HIV-1 replication with a superior resistance profile to zidovudine. Recently, we identified five novel 6-modified-3'-azido-ddG analogs that exhibit similar or superior anti-
Autor:
Steven J. Coats, Hongwang Zhang, Raymond F. Schinazi, Mervi Detorio, Brian D. Herman, James H. Nettles, John W. Mellors, Sarah Solomon, Aleksandr Obikhod, Sijia Tao, Nicolas Sluis-Cremer, Leda Bassit
Publikováno v:
European Journal of Medicinal Chemistry. 46:3832-3844
Microwave-assisted optimized transglycosylation reactions were used to prepare eleven modified l-3'-azido-2',3'-dideoxypurine nucleosides. These l-nucleoside analogs were evaluated against HIV and hepatitis B virus. The l-3'-azido-2',3'-dideoxypurine
Autor:
Brian D. Herman, Luigi A. Agrofoglio, Nicolas Sluis-Cremer, Raymond F. Schinazi, Vincent Roy, Steven J. Coats, Hongwang Zhang, Aleksandr Obikhod
Publikováno v:
Nucleosides Nucleotides Nucleic Acids
A series of hitherto unknown 3′-α-[1,2,3]-substituted triazolo-2′,3′-dideoxypyrimidine nucleoside analogues of the anti-HIV 3′-azido-3′-deoxythymidine (AZT) were synthesized through catalyzed alkyne-azide 1,3-dipolar cycloaddition (Huisgen
Publikováno v:
Analytical Chemistry. 82:1982-1989
Nucleoside reverse transcriptase inhibitors (NRTI) require intracellular phosphorylation, which involves multiple enzymatic steps to inhibit the human immunodeficiency virus type 1 (HIV-1). NRTI-triphosphates (NRTI-TP) compete with endogenous 2'-deox
Publikováno v:
Journal of Chromatography B. 877:3482-3488
A sensitive method was developed and validated for simultaneous measurement of an investigational antiviral nucleoside, Amdoxovir (DAPD), its deaminated metabolite 9-(β- d -1,3-dioxolan-4-yl)guanine (DXG), and Zidovudine (ZDV) in human plasma. This
Publikováno v:
Journal of Biological Chemistry. 283:34218-34228
Entecavir (ETV) is a potent antiviral nucleoside analogue that is used to treat hepatitis B virus (HBV) infection. Recent clinical studies have demonstrated that ETV is also active against the human immunodeficiency virus type 1 (HIV-1). Unlike all a
Autor:
Moira A. McMahon, Kimberly L. Rapp, Julian Tirado-Rives, Karen S. Anderson, Raymond F. Schinazi, Christopher M. Bailey, Chloe L. Thio, Robert F. Siliciano, Aleksandr Obikhod, Mervi Detorio, Robert A. Domaoal
Publikováno v:
J Biol Chem
The novel 2'-deoxyguanosine analog Entecavir (ETV) is a potent inhibitor of hepatitis B virus (HBV) replication and is recommended for treatment in human immunodeficiency virus type 1 (HIV-1) and HBV-co-infected patients because it had been reported
Autor:
Emilie Fromentin, Raymond F. Schinazi, Brenda I. Hernandez-Santiago, Selwyn J. Hurwitz, Aleksandr Obikhod
Publikováno v:
Antiviral Chemistry and Chemotherapy. 18:343-346
Amdoxovir, currently in Phase II clinical trials, is rapidly converted to 9-(β-D-1,3-dioxolan-4-yl)guanine (DXG) by adenosine deaminase in vitro and in humans. The cellular pharmacology of DXG in primary human lymphocytes, including dose-response re